Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2024 (Earliest event reported)
Reporting Period Referenced: First Quarter ended March 31, 2024
This filing primarily announces a change in the company's independent registered public accounting firm and references the release of Q1 2024 financial results via a press release.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release (Exhibit 99.1) and the Q1 2024 Form 10-Q, which are incorporated by reference but not detailed in this document.
Material Changes
- Change in Certifying Accountant: The Audit Committee dismissed Ernst & Young LLP (EY) as the independent registered public accounting firm, effective beginning in the second fiscal quarter of 2024.
- New Appointment: PricewaterhouseCoopers LLP (PwC) was appointed as the new independent registered public accounting firm, effective upon completion of standard client acceptance processes.
- Internal Control Status: A material weakness in internal control over financial reporting related to estimating costs for revenue license agreements (identified for the year ended Dec 31, 2023) remains in the process of remediation as of the Q1 2024 period.
Guidance, Outlook, and Risks
Management Commentary: The filing references an updated corporate presentation and an earnings call presentation released on May 9, 2024, which contain forward-looking statements regarding anticipated performance under the Tempus Agreement and Restated Agreement.
Risks and Contingencies:
- Forward-Looking Statements: The company cautions that statements regarding future performance are subject to risks and uncertainties that could cause actual results to differ materially.
- Internal Controls: The company did not maintain effective internal control over financial reporting as of December 31, 2023, due to the identified material weakness.
- Accountant Transition: No disagreements or reportable events occurred with the former auditor (EY) other than the previously disclosed material weakness.
Investor Verification Checklist
- Review the Q1 2024 Press Release (Exhibit 99.1) for specific revenue, net loss, and cash position figures.
- Verify the status of the material weakness remediation in the most recent Form 10-Q.
- Examine the updated corporate presentation (Exhibit 99.2) for details on the Tempus Agreement and Restated Agreement performance.
- Confirm the effective date of PwC's engagement and the transition timeline from EY.